期刊
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
卷 128, 期 6, 页码 1693-1696出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13813455.2020.1789170
关键词
Cognitive impairment; neuroinflammation; dopamine; glibenclamide
资金
- RFBR [20-015-00168]
With the progressively aging human population and increased occurrence of dysmetabolic disorders, cognitive impairment has become a major threat to national health. This article aims to review the available data on the widely used hypoglycemic drug glibenclamide and explore its potential relationship to the pathogenesis of cognitive impairment.
In the view of progressively aging human population and increased occurrence of dysmetabolic disorders, such as diabetes mellitus, cognitive impairment becomes a major threat to the national health. To date, the molecular mechanisms of cognitive dysfunction are partially described for diabetes and diseases of different nature, such as Alzheimer disease or Parkinson disease. The emergence of data pointing towards pleotropic effects of hypoglycaemic medicines indicates involvement of their targets in pathogenesis of cognitive impairment. We are aiming here to review available data on the most widely used hypoglycaemic drug, glibenclamide and find possible relationship of its targets to the pathogenesis of cognitive impairment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据